News | Nuclear Imaging | April 21, 2016

UltraSPECT Celebrates 10th Anniversary of Wide Beam Reconstruction Technology Approval

Company says technology for ultra-low dose, ultra-fast nuclear imaging has helped drive sales

UltraSPECT, 10th anniversary, WBR technology, Wide Beam Reconstruction, FDA approval, nuclear imaging

April 21, 2016 – UltraSPECT Inc. announced the 10th anniversary of the U.S. Food and Drug Administration (FDA) approval of its Wide Beam Reconstruction (WBR) technology. The technology employs an iterative reconstruction imaging algorithm to enable lower dose and shorter time imaging for nuclear medicine exams.

An early entrant to the market, UltraSPECT has had double-digit growth in both annual revenue and annual units sold for the last few years. Factors like the recently introduced American Society of Nuclear Cardiology (ASNC) low-dose guidelines, heightened patient awareness to the risks of exposure to radiation, and new Centers for Medicare and Medicaid Services (CMS) reimbursement penalties have accelerated the quest by hospitals to implement emerging low-dose and ultra-low dose nuclear medicine technologies. 

In 2006, UltraSPECT introduced to the U.S. market the first application for shorter-time patient imaging both for oncology and cardiology exams, and followed that with the enhanced technology for both shorter-time and lower-dose imaging in 2008. The resulting benefit is enhanced value to physicians, technologists, patients, administrators and radiopharmaceutical suppliers of reduced dose, shorter scans and increased patient comfort with images as good, if not better in diagnostic quality, than those provided with traditional single photon emission computed tomography (SPECT) acquisition.

UltraSPECT has achieved the following key milestones:

  • Double-digit revenue growth for the past three years;
  • More than 200 units sold between 2013-2015;
  • Installations in 46 states;
  • 16 distribution partners, including 8 different radiopharmaceutical pharmacies;
  • Compatibility with 41 different gamma cameras and 12 workstations representing all the major manufacturers; and
  • 100% field validation

“What started as a handful of installations have evolved into tremendous market demand as everyone — from patients and technologists to physicians, pharmacies and pharmacy staff — is benefiting,” said Wayne Wong, owner and vice president, Nuclear Diagnostic Products. “We believed in the product from the beginning and trusted that the nuclear medicine would catch on to the low-dose movement, and being an early partner of UltraSPECT has been a great decision for us.”

While early adopters were instrumental in setting the foundation for UltraSPECT, recent expansion has been in part due to a number of other market conditions, including changes from regulatory groups. They include the ASNC guidelines for low-dose imaging that took effect in January 2015, along with the Physician Quality Reporting System (PQRS) requirement to obtain an additional 2 percent in CMS reimbursement. Other industry pressures influencing the market are:

  • Growing shortage of Tc-99m isotope;
  • Greater awareness by patients of the need for low-dose imaging supported, in part, by action groups like Image Wisely, launched at the Radiological Society of North America (RSNA) 2010 annual meeting; and
  • Growing cost pressures. At a fraction of the cost of a brand-new camera, UltraSPECT also provides one of the most cost-effective solutions to the nuclear medicine market, according to the company.

For more information: www.ultraspect.com

Related Content

News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...